Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Conditions
Interventions
BPS804 20mg/Kg
Placebo to 20mg/Kg BPS804
Locations
5
United States
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Berlin, New Jersey, United States
Novartis Investigative Site
Duncansville, Pennsylvania, United States
Start Date
July 1, 2011
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
September 15, 2022
NCT06558188
NCT06449742
NCT07474571
NCT06541548
NCT07254429
NCT07412782
Lead Sponsor
Ultragenyx Pharmaceutical Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions